Clinical Trial Update: A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing deucravacitinib to placebo in active psoriatic arthritis patients (biologic-naïve or prior TNF inhibitor exposure) has posted results;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Deucravacitinib (deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriatic Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-13